On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
BackgroundInflammation is a factor that promotes tumor progression and immunosuppression. Lung immune prognostic index (LIPI) is a non-invasive and easily calculated indicator of inflammation. This study aimed to investigate whether continuous assessment of LIPI has predictive value for chemoimmunot...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1173025/full |
| _version_ | 1797820983380279296 |
|---|---|
| author | Anning Xiong Jianlin Xu Shuyuan Wang Runbo Zhong Jun Lu Tianqing Chu Wei Zhang Ying Li Xiaoxuan Zheng Baohui Han Wei Nie Hua Zhong Xueyan Zhang |
| author_facet | Anning Xiong Jianlin Xu Shuyuan Wang Runbo Zhong Jun Lu Tianqing Chu Wei Zhang Ying Li Xiaoxuan Zheng Baohui Han Wei Nie Hua Zhong Xueyan Zhang |
| author_sort | Anning Xiong |
| collection | DOAJ |
| description | BackgroundInflammation is a factor that promotes tumor progression and immunosuppression. Lung immune prognostic index (LIPI) is a non-invasive and easily calculated indicator of inflammation. This study aimed to investigate whether continuous assessment of LIPI has predictive value for chemoimmunotherapy in non-small cell lung cancer (NSCLC) patients receiving first-line programmed cell death 1 (PD-1) inhibitor plus chemotherapy. In addition, the predictive value of LIPI in patients with the negative or low programmed death-ligand (PD-L1) expression level was also explored.MethodsTotally, 146 stage IIIB to IV or recurrent NSCLC patients who received first-line PD-1 inhibitor combined with chemotherapy were enrolled in this study. The LIPI scores were calculated at baseline (PRE-LIPI) and after two cycles of the combined administration (POST-LIPI). This study analyzed the relationship between good/intermediate/poor PRE (POST)-LIPI and objective response rate (ORR), as well as progression-free survival (PFS) using logistic and Cox regression models. In addition, the predictive value of LIPI in patients with the negative or low PD-L1 expression level was explored. To further assess the potential predictive value of continuous assessment of LIPI, the association of sum (LIPI) [sum(LIPI) = PRE-LIPI + POST-LIPI] and PFS was analyzed in the 146 patients.ResultsCompared with good POST-LIPI group, significantly lower ORRs were found in intermediate POST-LIPI (P = 0.005) and poor POST-LIPI (P = 0.018) groups. Moreover, intermediate POST-LIPI (P =0.003) and poor POST-LIPI (P < 0.001) were significantly associated with a shorter PFS than good POST-LIPI. Additionally, a higher POST-LIPI score was still significantly associated with poorer treatment efficacy in patients with the negative or low PD-L1 expression level. Moreover, a higher sum (LIPI) score was significantly correlated with a shorter PFS (P = 0.001).ConclusionContinuous assessment of LIPI might be an effective method for predicting the efficacy of PD-1 inhibitor plus chemotherapy in NSCLC patients. In addition, in patients with the negative or low PD-L1 expression level, it might also have a potential predictive value for therapeutic efficacy to continuously assess LIPI during the treatment. |
| first_indexed | 2024-03-13T09:46:09Z |
| format | Article |
| id | doaj.art-0867cb6150234de1964f41fb0472914a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T09:46:09Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0867cb6150234de1964f41fb0472914a2023-05-25T04:13:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11730251173025On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancerAnning XiongJianlin XuShuyuan WangRunbo ZhongJun LuTianqing ChuWei ZhangYing LiXiaoxuan ZhengBaohui HanWei NieHua ZhongXueyan ZhangBackgroundInflammation is a factor that promotes tumor progression and immunosuppression. Lung immune prognostic index (LIPI) is a non-invasive and easily calculated indicator of inflammation. This study aimed to investigate whether continuous assessment of LIPI has predictive value for chemoimmunotherapy in non-small cell lung cancer (NSCLC) patients receiving first-line programmed cell death 1 (PD-1) inhibitor plus chemotherapy. In addition, the predictive value of LIPI in patients with the negative or low programmed death-ligand (PD-L1) expression level was also explored.MethodsTotally, 146 stage IIIB to IV or recurrent NSCLC patients who received first-line PD-1 inhibitor combined with chemotherapy were enrolled in this study. The LIPI scores were calculated at baseline (PRE-LIPI) and after two cycles of the combined administration (POST-LIPI). This study analyzed the relationship between good/intermediate/poor PRE (POST)-LIPI and objective response rate (ORR), as well as progression-free survival (PFS) using logistic and Cox regression models. In addition, the predictive value of LIPI in patients with the negative or low PD-L1 expression level was explored. To further assess the potential predictive value of continuous assessment of LIPI, the association of sum (LIPI) [sum(LIPI) = PRE-LIPI + POST-LIPI] and PFS was analyzed in the 146 patients.ResultsCompared with good POST-LIPI group, significantly lower ORRs were found in intermediate POST-LIPI (P = 0.005) and poor POST-LIPI (P = 0.018) groups. Moreover, intermediate POST-LIPI (P =0.003) and poor POST-LIPI (P < 0.001) were significantly associated with a shorter PFS than good POST-LIPI. Additionally, a higher POST-LIPI score was still significantly associated with poorer treatment efficacy in patients with the negative or low PD-L1 expression level. Moreover, a higher sum (LIPI) score was significantly correlated with a shorter PFS (P = 0.001).ConclusionContinuous assessment of LIPI might be an effective method for predicting the efficacy of PD-1 inhibitor plus chemotherapy in NSCLC patients. In addition, in patients with the negative or low PD-L1 expression level, it might also have a potential predictive value for therapeutic efficacy to continuously assess LIPI during the treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1173025/fulllung immune prognostic indexperipheral blood cellsimmune-checkpoint inhibitorscombination chemotherapynon-small cell lung cancer |
| spellingShingle | Anning Xiong Jianlin Xu Shuyuan Wang Runbo Zhong Jun Lu Tianqing Chu Wei Zhang Ying Li Xiaoxuan Zheng Baohui Han Wei Nie Hua Zhong Xueyan Zhang On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer Frontiers in Immunology lung immune prognostic index peripheral blood cells immune-checkpoint inhibitors combination chemotherapy non-small cell lung cancer |
| title | On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer |
| title_full | On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer |
| title_fullStr | On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer |
| title_full_unstemmed | On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer |
| title_short | On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer |
| title_sort | on treatment lung immune prognostic index is predictive for first line pd 1 inhibitor combined with chemotherapy in patients with non small cell lung cancer |
| topic | lung immune prognostic index peripheral blood cells immune-checkpoint inhibitors combination chemotherapy non-small cell lung cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1173025/full |
| work_keys_str_mv | AT anningxiong ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT jianlinxu ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT shuyuanwang ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT runbozhong ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT junlu ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT tianqingchu ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT weizhang ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT yingli ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT xiaoxuanzheng ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT baohuihan ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT weinie ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT huazhong ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer AT xueyanzhang ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer |